News

Conference Coverage

Pacritinib Therapy May Improve Hemoglobin Responses Among Patients With Myelofibrosis

09/03/2025

Raajit Rampal, MD, PhD

Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.

Raajit Rampal, MD, PhD shares...

09/03/2025

Oncology

Conference Coverage

BET Inhibitor INCB057643 Shows Promising Efficacy for Treatment of Relapsed/Refractory Myelofibrosis

07/14/2025

Emily Estrada

The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.

The small-molecular BET...

07/14/2025

Oncology

Conference Coverage

BET Inhibitor INCB057643 Shows Promising Efficacy for Treatment of Relapsed/Refractory Myelofibrosis

07/14/2025

Emily Estrada

The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.

The small-molecular BET...

07/14/2025

Oncology

Conference Coverage

Imetelstat Combined With Ruxolitinib Demonstrates Promising Activity for Patients With Myelofibrosis: IMproveMF Trial

07/14/2025

Emily Estrada

The combination of imetelstat plus ruxolitinib for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis demonstrated manageable safety and promising activity, according to interim results from the IMproveMF trial.

The combination of imetelstat...

07/14/2025

Oncology

Conference Coverage

Imetelstat Combined With Ruxolitinib Demonstrates Promising Activity for Patients With Myelofibrosis: IMproveMF Trial

07/14/2025

Emily Estrada

The combination of imetelstat...

07/14/2025

Oncology

Conference Coverage

Rusfertide Improves Hematocrit Control for Certain Patients With Myeloproliferative Neoplasms

06/03/2025

Andrew Kuykendall

Andrew Kuykendall, MD, discusses the results of the phase 3 VERIFY trial which compared rusfertide vs placebo for certain patients with myeloproliferative neoplasms.

Andrew Kuykendall, MD, discusses...

06/03/2025

Oncology

Conference Coverage

Pulmonary Hypertension Prevalent Among Patients With Myelofibrosis

06/03/2025

Daehyun Lee,  MD

Daehyun Lee, MD, discusses results from a retrospective cohort study which found that pulmonary hypertension is prevalent among patients with myelofibrosis and is associated with increased cardiovascular morbidity, including heart failure.

Daehyun Lee, MD, discusses...

06/03/2025

Oncology

News

Combining Ruxolitinib With Novel Agents Shows Promise as Treatment for Patients With Myelofibrosis

05/31/2025

Emily Estrada

The combination of ruxolitinib plus novel agents such as siremadlin demonstrated promising efficacy and safety among patients with myelofibrosis who had suboptimal response to ruxolitinib monotherapy.

The combination of ruxolitinib...

05/31/2025

Oncology

News

PXS-5505 Demonstrates Early Anti-Fibrotic Activity and Tolerability for Patients With R/R Myelofibrosis

05/20/2025

Emily Estrada

For patients with MF who are refractory to Janus kinase inhibitor treatment, novel pan-lysyl oxidase inhibitor PXS-5505 demonstrated promising safety and tolerability, according to a phase 1/2a trial.

For patients with MF who are...

05/20/2025

Oncology

News

Mutation Clearance After Allogeneic Stem Cell Transplantation as Prognostic Indicator for Patients With Myelofibrosis

03/17/2025

Emily Estrada

For patients with myelofibrosis undergoing allogeneic hematopoietic stem cell transplantation, mutation driver clearance at 30 days was associated with improved cancer outcomes, according to study results.

For patients with myelofibrosis...

03/17/2025

Oncology

Recent News

News

Sequential HER2-Targeted Therapy Following Trastuzumab Deruxtecan Discontinuation Among Patients With HER2-Positive Metastatic Breast Cancer

09/12/2025

Stephanie Holland

Sequential HER2-targeted therapy following trastuzumab deruxtecan discontinuation demonstrated clinical promise among patients with HER2-positive metastatic breast cancer who responded to T-DXd however discontinued treatment due to adverse...

Sequential HER2-targeted therapy...

09/12/2025

Oncology

News

Durvalumab Plus Platinum-Based Chemotherapy for Treatment-Naive Patients With Extensive-Stage Small Cell Lung Cancer

09/10/2025

Stephanie Holland

According to exploratory subgroup analysis results from the phase 3 CASPIAN trial, durvalumab plus etoposide and carboplatin or cisplatin demonstrated efficacy and safety regardless of age or sex among treatment-naive patients with...

According to exploratory...

09/10/2025

Oncology

FDA Approval

FDA Accepts New Drug Application for Relacorilant as a Treatment for Patients With Platinum-Resistant Ovarian Cancer

09/10/2025

Allison Casey

The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.

The FDA has accepted an NDA for...

09/10/2025

Oncology

News

Real-World Analysis of Neoadjuvant Immune Checkpoint Inhibition for Patients With dMMR/MSI Nonmetastatic Colon Cancer

09/10/2025

Stephanie Holland

According to results from a retrospective, observational study, neoadjuvant immune checkpoint inhibitors were effective and safe among patients with mismatch repair-deficient microsatellite instability nonmetastatic colon cancer.

According to results from a...

09/10/2025

Oncology

FDA Approval

FDA Approves Selumetinib Granules and Capsules for Pediatric Patients With NF1-Associated Symptomatic and Inoperable Plexiform Neurofibromas

09/10/2025

Stephanie Holland

The FDA has approved selumetinib granules and capsules for pediatric patients ≥ 1 year of age with neurofibromatosis type 1 who have symptomatic and inoperable plexiform neurofibromas.

The FDA has approved selumetinib...

09/10/2025

Oncology

News

Second-Line Irinotecan Liposome-Based Treatment Modalities Demonstrate Efficacy and Safety Among Patients With Advanced Unresectable Pancreatic Cancer

08/28/2025

Stephanie Holland

According to results from a real-world study, irinotecan liposome-based regimens in the second-line setting demonstrated both efficacy and safety among patients with advanced unresectable pancreatic cancer.

According to results from a...

08/28/2025

Oncology

News

Addition of Tocilizumab to First-Line Gemcitabine Plus Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer

08/28/2025

Stephanie Holland

According to results from the phase 2 PACTO study, the addition of tocilizumab to first-line gemcitabine plus nab-paclitaxel did not significantly improve clinical outcomes among patients with advanced pancreatic cancer.

According to results from the...

08/28/2025

Oncology

News

Dual Immune Checkpoint Blockade Plus Radiotherapy Fails to Improve Outcomes Among Newly Diagnosed Patients With MGMT-Unmethylated Glioblastoma

08/28/2025

Stephanie Holland

According to results from a phase 2 trial, radiotherapy in addition to dual immune checkpoint blockade with ipilmumab and nivolumab failed to improve outcomes compared to radiotherapy plus single-agent temozolomide among newly diagnosed adult...

According to results from a...

08/28/2025

Oncology

News

Intratumoral Clostridium Novyi-Nontoxic Plus Pembrolizumab Demonstrates Clinical Promise Among Patients With Treatment-Refractory Advanced Solid Tumors

08/27/2025

Stephanie Holland

According to results from a phase 1b study, clostridium novyi-nontoxic plus pembrolizumab demonstrated clinical promise among patients with treatment-refractory advanced solid tumors.

According to results from a...

08/27/2025

Oncology

News

Afatinib Plus Carboplatin and Pemetrexed Demonstrates Efficacy, Safety Among Patients WIth Advanced EGFR-Mutated Non-Small Cell Lung Cancer

08/27/2025

Stephanie Holland

According to results from the NEJ025B study, afatinib plus carboplatin and pemetrexed demonstrated promising efficacy and safety among patients with EGFR-mutated advanced non-small cell lung cancer who experienced disease progression after...

According to results from the...

08/27/2025

Oncology